Weiss Ratings Reiterates Sell (D-) Rating for 4D Molecular Therapeutics (NASDAQ:FDMT)

Key Points

• Weiss Ratings has reaffirmed a sell (D-) rating for 4D Molecular Therapeutics (NASDAQ: FDMT) amid mixed analyst opinions.
• The stock is currently trading at $4.36 with a market capitalization of approximately $202 million and an average target price of $29.56.
• Recent earnings report indicated a loss of ($0.86) EPS, missing estimates and highlighting negative trends in return on equity and net margin.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings in a note issued to investors on Tuesday,Weiss Ratings reports.

FDMT has been the subject of a number of other reports. Chardan Capital reiterated a "buy" rating and issued a $25.00 price target on shares of 4D Molecular Therapeutics in a research note on Thursday, July 3rd. Barclays lowered their target price on 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating for the company in a report on Friday, May 9th. Finally, The Goldman Sachs Group cut their price target on 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $29.56.

4D Molecular Therapeutics Trading Down 6.0%

FDMT stock opened at $4.36 on Tuesday. The stock has a market capitalization of $202.00 million, a P/E ratio of -1.37 and a beta of 2.81. 4D Molecular Therapeutics has a 12 month low of $2.23 and a 12 month high of $18.14. The firm has a 50-day moving average price of $4.11 and a 200-day moving average price of $4.03.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.84) by ($0.02). 4D Molecular Therapeutics had a negative return on equity of 33.26% and a negative net margin of 767,126.06%. As a group, equities analysts predict that 4D Molecular Therapeutics will post -2.84 EPS for the current fiscal year.

Hedge Funds Weigh In On 4D Molecular Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Kera Capital Partners Inc. bought a new stake in 4D Molecular Therapeutics in the second quarter valued at approximately $89,000. Acadian Asset Management LLC raised its holdings in 4D Molecular Therapeutics by 1,103.4% during the 1st quarter. Acadian Asset Management LLC now owns 400,606 shares of the company's stock worth $1,290,000 after purchasing an additional 367,317 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in shares of 4D Molecular Therapeutics in the 1st quarter worth approximately $39,000. Millennium Management LLC boosted its stake in shares of 4D Molecular Therapeutics by 15.0% in the 1st quarter. Millennium Management LLC now owns 1,633,987 shares of the company's stock valued at $5,278,000 after purchasing an additional 213,264 shares during the last quarter. Finally, BVF Inc. IL increased its position in shares of 4D Molecular Therapeutics by 70.8% during the first quarter. BVF Inc. IL now owns 4,561,289 shares of the company's stock worth $14,733,000 after buying an additional 1,890,647 shares during the period. 99.27% of the stock is currently owned by institutional investors.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.